The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.

BioNTech and Roche subsidiary Genentech are discontinuing testing of their jointly developed personalized cancer vaccine in colorectal cancer patients. The companies were testing the mRNA vaccine ...

Regulators approved the FGFR1/2/3 inhibitor based on data showing a 42.5 percent objective response rate and 16.6 months of median overall survival.

For patients with microsatellite instability of mismatch repair deficiency, the final decision cements access to the drug, which was previously offered provisionally.

The firm is testing the next dose level of RV-01 in a Phase I/IIa study after clearance from a safety and monitoring committee.

Three years after announcing the trial, the company dosed the first patient with the therapy, which targets kappa myeloma antigens.

This marks the company's first study in POLG-mediated primary mitochondrial disease, after completing a Phase I trial in healthy volunteers.

The study partially fulfills a goal set in the company's latest strategic plan that emphasizes late-stage and pivotal trials.

NEW YORK – More breast cancer patients in Canada may soon have access to Roche's HER2-targeted treatment Perjeta (pertuzumab) after successful pricing negotiations between the biotech and the ...

NEW YORK – Jazz Pharmaceuticals, a company that sells precision oncology and other therapeutics, on Monday said it plans to purchase Actio Biosciences to expand its rare epilepsy portfolio.

NEW YORK – Create Medicines on Thursday said it plans to launch a first-in-human trial of CRT-402, the company's lead in vivo CAR T-cell therapy candidate that it's developing for multiple autoimmune ...